8 月 4 日,药物临床试验登记与信息公示平台官网显示,东阳光药登记了一项HEC-007 注射液的 I 期临床试验。公开资料显示,这是该药首次启动临床。截图来源:药物临床试验登记与信息公示平台官网这是一项单中心、随机、双盲、安慰剂对照研究,旨在评价 HEC-007 注射液在健康受试者中单次给药和在超重或肥胖受试者中多次给药的安全性、耐受性、药代动力学及药效学。主要终点包括安全性:不良事件、实验室...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.